Is TB-500 the same as thymosin beta-4?

FDA names a seven-residue LKKTETQ fragment; the parent has 43 residues. An analytical study found acetylated fragment in tested material, but vendor naming does not verify every vial.

Is TB-500 FDA-approved?

A favorable advisory vote is not FDA product approval or a final list change. Exact product and current final/interim compounding conditions require separate assessment.

Does TB-500 heal injuries faster?

The 2026 rat repair findings are encouraging but do not establish controlled human fragment healing, a dose or return-to-play timeline.

What did the FDA say about TB-500?

FDA staff evaluation, favorable committee recommendation, nomination withdrawal and final policy are distinct. None alone establishes a general treatment pathway.

Controlled human fragment safety is not established by parent studies or short uncontrolled reports. Unknown does not prove either universal safety or harm.

What dose of TB-500 do people use?

Community loading/maintenance amounts are unvalidated reports, not an established safe human regimen.

Is TB-500 banned in sports?

WADA prohibits relevant thymosin-beta-4 derivatives includingTB-500. Sport rules and clinical access are separate.

TB-500 passed the PCAC vote. Is it legal now?

A committee recommendation is advisory. Verify actual agency action and its conditions rather than equating the vote with immediate product approval or blanket legal clearance.

TB-500 Peptide: What the Evidence Shows After the July 2026 FDA Vote

By the Peptide Dossier Editorial TeamUpdated October 27, 2026How we source

TB-500 identity, limited evidence and the July 2026 advisory recommendation require separate interpretation. A favorable vote is not product approval or a final compounding rule; parent-protein research and TB-labelled products are not interchangeable.

What TB-500 Actually Is

FDA’s TB-500 assessment identifies the seven-residue thymosin beta-4 fragment LKKTETQ. Full-length thymosin beta-4 has 43 residues. The original analytical product study identified an acetylated fragment in tested material. Names on other vials do not independently verify identity. Parent-protein human wound/eye trials cannot establish the fragment’s outcomes.

The July 2026 PCAC Vote and What It Decided

The archived transcript of the official FDA-linked July 23, 2026 webcast records separate TB-500 free-base and acetate questions, followed by eight yes votes, six no votes and one abstention for each. This is a favorable advisory recommendation. The browser-transcript archive has transcription errors and is not certified written minutes. FDA staff had recommended against listing in its substance evaluation. The committee and staff have different roles; neither a vote nor a withdrawn nomination is finished-product approval. The FDA category record distinguishes withdrawal of the TB nomination from a final positive 503A-list action. Current authority must be checked against the applicable final and interim policies and exact product; a bare statement that a substance is absent from one list does not inventory every legal condition.

The Human Evidence Gap

The assessed fragment evidence does not establish controlled human tendon-repair or performance benefit. Full-length human studies and unspecified TB4 materials in uncontrolled combination reports require separate identity/route interpretation. Those observations must be interpreted according to their actual product and route.

A 2026 rat Achilles-repair study randomized 32 rats in four groups, with four per group for each endpoint. Daily intraperitoneal treatment for 30 days produced selected favorable mechanical/histological outcomes: TB-labelled treatment improved load, while BPC had selected collagen findings without load benefit; combined treatment did not establish added superiority over monotherapy. Vendor labeling did not independently establish the peptide sequence. This is encouraging preclinical work, not a human dose, injection-site benefit or return-to-play timeline.

Parent-protein clinical work deserves separate attention. Ruff’s IV healthy-volunteer study examined short-term safety/PK in four cohorts, not injury healing. Guarnera’s phase-II abstract describes 73 randomized venous-stasis-ulcer patients using topical parent Tβ4; 0.03% may have accelerated healing, particularly in smaller/less severe ulcers. This tentative positive outcome does not establish a fragment injection dose or general tissue-repair effect.

Claimed Uses vs What Is Supported

Claims include tendon, muscle, joint, hair and cardiac recovery. Parent-protein experiments and selected rat mechanical outcomes support further research, but do not establish those human fragment benefits. A diagnosis, appropriate comparator, validated function and follow-up are needed to evaluate a clinical repair claim.

Dosing: Convention, Not Data

Vendor/community loading and maintenance schedules are reported practices, not validated safe or effective regimens. No home dose or local injection advantage follows from the assessed evidence. 2026 WADA rules prohibit relevant thymosin-beta-4 derivatives including TB-500; sporting eligibility and FDA access are separate questions.

Supply Quality Is a Separate Risk

Identity, active content, impurities and microbial/endotoxin evidence answer different quality questions. Research labeling or a COA does not establish human-use suitability, sterility or lawful access. An unapproved product is not automatically a lawful off-label prescription; actual final/interim conditions and the exact preparation matter.

Related reading: peptide grey market risks.

Related reading: peptide testing and quality.

What Happens Next

A regulatory timetable cannot be predicted from a committee vote. Verify an actual agency action and its operative conditions rather than promising access or no change by a calendar date. Native MOTS-c registry work, endogenous observations and modified CB4211 research are distinct; the earlier blanket zero-human-studies description is not an accurate current summary.